Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.
Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter A
GENERIC NAME |
TRADE NAME |
CONDITION |
STUDY CODE |
STUDY NAME |
ACCESS TO STUDY / PROTOCOL |
ACCESS TO RESULTS |
---|---|---|---|---|---|---|
AAV2-SFLT01 |
Not Marketed |
Age-Related Macular Degeneration |
MSC12870 |
NA |
||
ABCA4 GENE THERAPY |
Not Marketed |
Stargardt's Disease |
TDU13583 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
TES10897 |
QUTIE |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
ARD6122 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
ARD6123 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC6125 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC6546 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
ARD6772 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC10262 |
VELOUR |
|
|
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC10261 |
VITAL |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC10547 |
VANILLA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC10668 |
AFFIRM |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
EFC10668 |
AFFIRM |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
TCD11382 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
TCD11470 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Colorectal cancer |
AFLIBC06561 |
AMOR |
||
AFLIBERCEPT |
Zaltrap |
Cancer |
TCD6117 |
NA |
NA |
|
AFLIBERCEPT |
Zaltrap |
Colorectal cancer |
EFC11338 |
AFLAME |
||
AFLIBERCEPT |
Zaltrap |
Colorectal cancer |
EFC11885 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Non Hodgkins Lymphoma |
TCD10173 |
NA |
||
AFLIBERCEPT |
Zaltrap |
Colorectal cancer |
AFLIBL06266 |
AFEQT |
||
AFLIBERCEPT |
Zaltrap |
Colorectal cancer |
AFLIBC06097 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-005-99 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-006-99* |
NA |
|
|
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-007-99* |
NA |
|
|
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-008-00 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-016-01 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-017-01 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-019-01* |
NA |
|
|
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-022-02 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL02503 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL06207 |
FIELD |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL03204 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL-1-002-98* |
NA |
|
|
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL19110 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
AGAL19412 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
DIREGC07006 |
NA |
||
AGALSIDASE BETA |
Fabrazyme |
Fabry Disease |
FB9702-01* |
NA |
|
|
ALEMTUZUMAB |
Campath |
Leukemia |
CAM203 |
NA |
||
ALEMTUZUMAB |
Campath |
Leukemia |
CAM211* |
NA |
|
|
ALEMTUZUMAB |
Campath |
Leukemia |
CAM307* |
NA |
||
ALEMTUZUMAB |
Campath |
Leukemia |
CAM314 |
NA |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
ALEMLL08091 |
LemCourse |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
ASY15905 |
LEMTRADA-ITP |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
CAMMS223 |
NA |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
CAMMS323 |
CARE-MS I |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
CAMMS32400507 |
CARE-MS II |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
CAMMS03409 |
CARE-MS II |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
LPS13649 |
TOPAZ |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
LPS13650 |
EMERALD |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
TDU14260 |
SCALA |
||
ALEMTUZUMAB |
Not Marketed |
Multiple Sclerosis |
TDU13475 |
NA |
||
ALEMTUZUMAB |
Not Marketed |
Multiple Sclerosis |
TDU14981 |
NA |
||
ALEMTUZUMAB |
Lemtrada |
Multiple Sclerosis |
OBS13436 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
ALFUS_L_01241 |
SAMBA_THAILAND |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
ALFUS_L_01667 |
SAMBA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Benign Prostatic Hyperplasia |
DRI5234 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Benign Prostatic Hyperplasia |
EFC4428 |
ALFAURUS |
||
ALFUZOSIN |
Uroxatral, Xatral |
Benign Prostatic Hyperplasia |
EFC4485 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Neurogenic Urinary Bladder |
EFC5722 |
ALPHACHIN |
||
ALFUZOSIN |
Uroxatral, Xatral |
Benign Prostatic Hyperplasia |
EFC5791 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Hydronephosis Neurogenic Bladder |
EFC6269 |
ALPHAHYDRO |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
L_8472 |
ALF-ACUTE |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
L_8758 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
L_8819 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
L_8935 |
ALEX-XL |
||
ALFUZOSIN |
Uroxatral, Xatral |
Urologic Diseases |
L_9397 |
ALF-RIK |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
L_9645 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Calculi |
L_9795 |
ALF-STONE |
||
ALFUZOSIN |
Uroxatral, Xatral |
Benign Prostatic Hyperplasia |
LTS5235 |
NA |
||
ALFUZOSIN |
Uroxatral, Xatral |
Urinary Bladder Neurogenic |
PKM6270 |
ALPHACHIP |
||
ALFUZOSIN |
Uroxatral, Xatral |
Prostatic Diseases |
PM_L_0168 |
ALFONE CHINA |
||
ALGLUCOSIDASE ALFA |
Lumizyme |
Pompe Disease Glycogen Storage Disease Type II (GSD II) |
MSC12790/ AGLU07710 |
PAPAYA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU01602 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU01702 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU02704 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU02804 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU03206 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU03306 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU03707_MSC12817 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU03807 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU07310 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU07510 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
AGLU09411 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme |
Pompe Disease |
ALGMYL08718 |
APOLLO-IOPD |
||
ALGLUCOSIDASE ALFA |
Myozyme® Lumizyme® |
Pompe Disease; Glycogen Storage Disease Type II (GSD II); Acid Maltase Deficiency Disease |
LTS12869 |
NA |
||
ALGLUCOSIDASE ALFA |
Myozyme®/Lumizyme® |
Pompe Disease |
AGLU06909/LTS13930 |
NA |
||
ALIROCUMAB |
Praluent |
Acute Coronary Syndrome |
ALIROL08069 |
ODYSSEY J-IVUS |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
DFI11565 |
NA |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
DFI11566 |
NA |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
DFI12361 |
NA |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
DFI14223 |
ODYSSEY KIDS |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC14074 |
NA |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC11568 |
ODYSSEY COMBO I |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC11569 |
ODYSSEY COMBO II |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC11716 |
ODYSSEY MONO |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC12492 |
ODYSSEY FH I |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC12732 |
ODYSSEY HIGH FH |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC13672 |
ODYSSEY JAPAN |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC13786 |
ODYSSEY CHOICE II |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC13889 |
ODYSSEY EAST |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC14305 |
ODYSSEY-NIPPON |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
EFC14660 |
NA |
||
ALIROCUMAB |
Praluent |
Dyslipidemia |
LPS14354 |
ODYSSEY DM-Dyslipidemia |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
LPS14245 |
ODYSSEY APPRISE |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
LPS14355 |
ODYSSEY DM-Insulin |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
LTS11717 |
ODYSSEY LONG TERM |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
LTS13463 |
ODYSSEY OLE |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
MSC14864 |
NA |
||
ALIROCUMAB |
Praluent |
Hypercholesterolemia |
POP12671 |
NA |
||
ALIROCUMAB |
Praluent |
Cardiovascular Diseases |
EFC11570 |
NA |
||
AMBROXOL |
Not marketed |
Acute Pharyngitis |
LPS15328 |
DELICIOUS |
||
Amcenestrant |
Not marketed |
Breast Cancer |
ACT16106 |
AMEERA-4 |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC4846 |
ZEPHIR |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC5041 |
ORION |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC5116 |
PHOENIX |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC5374 |
NA |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC5379 |
NA |
||
AMIBEGRON |
Not marketed |
Generalized anxiety disorder |
EFC5891 |
ELECTRA |
||
AMIBEGRON |
Not marketed |
Generalized anxiety disorder |
EFC5892 |
LIBRA |
||
AMIBEGRON |
Not marketed |
Generalized anxiety disorder |
EFC5893 |
AQUARIUS |
||
AMIBEGRON |
Not marketed |
Generalized anxiety disorder |
EFC5895 |
GEMINI |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC6224 |
ALBERIO |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
EFC6607 |
SIRIUS |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
LTE5376 |
CALYPSO |
||
AMIBEGRON |
Not marketed |
Generalized anxiety disorder |
LTE5894 |
VEGA |
||
AMIBEGRON |
Not marketed |
Major Depressive Disorder |
LTS4848 |
NA |
||
AMISULPRIDE |
Solian |
Schizophrenia |
AMISU_L_01008 |
AMIMIND |
||
AMISULPRIDE |
Solian |
Bipolar Disorder |
C_8428 |
SOLMANIA |
||
AMISULPRIDE |
Solian |
Schizophrenia |
L_8967 |
AMIRISMIND |
NA |
|
AMISULPRIDE |
Solian |
Schizophrenia |
L_8968 |
NA |
||
AMISULPRIDE |
Solian |
Schizophrenia |
L_9517 |
ASAP |
||
AMISULPRIDE |
Solian |
Schizophrenia |
PM_L_0055 |
SOLIACS |
||
AMISULPRIDE |
Solian |
Schizophrenia |
AMISUL06155 |
ESCAPE |
||
AMLITELIMAB |
Not marketed |
Atopic Dermatitis |
ACT17369 |
NA |
||
ANTIBODY DRUG CONJUGATE |
Not Marketed |
Neoplasm Malignant |
TED14147 |
NA |
||
ANTIBODY-DRUG CONJUGATE TARGETING SIALOGLYCOTOPE CA6/HUDS6 |
Not Marketed |
Triple Negative Breast Cancer |
TED10499 |
NA |
||
ANTI-CXCR5 MAB |
Not Marketed |
Systemic Lupus Erythematosus |
TDR11407 |
NA |
||
ANTI-PNAG MONOCLONAL ANTIBODY |
Not marketed |
Infection prophylaxis |
PKD11791 |
NA |
||
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SANG-93-3-K-THY-R* |
NA |
|
|
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SANG-96-3-K-THY-I* |
NA |
|
|
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SMC-101-1002* |
NA |
|
|
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SMC-101-1007* |
NA |
|
|
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SMC-101-1008* |
NA |
|
|
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SMC-101-1009* |
NA |
|
|
ANTI-THYMOCYTE GLOBULIN (RABBIT) |
Thymoglobulin |
kidney transplant rejection |
SMC-534-1003* |
NA |
|
|
ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC FUSION PROTEIN |
Eloctate |
Hemophilia A |
EFC16225 (997HA306) |
NA |
||
ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC FUSION PROTEIN |
Eloctate |
Hemophilia A |
LPS16473 |
verITI-8 Study |
||
Alogliptin |
Nesina |
Diabetes Mellitus, Type 2 |
ALOGLC08867 |
ACADEMIC |
||
ARTESUNATE |
Arsucam |
Malaria |
ARTEN_L_00848 |
ACT MALI |
||
ARTESUNATE |
Arsucam |
Malaria |
PM_L_0163 |
ATOL |
||
ARTESUNATE + AMODIAQUINE |
Coarsucam |
Malaria |
ARAMF_L_01570 |
NA |
||
ARTESUNATE + AMODIAQUINE |
Coarsucam |
Malaria |
ARAMF_L_02873 |
NA |
||
ARTESUNATE + AMODIAQUINE |
Coarsucam |
Malaria |
PM_L_0164 |
ATAQ EASY |
||
ARTESUNATE + AMODIAQUINE |
Coarsucam |
Malaria |
ARAMF_L_02661 |
NA |
||
ARTESUNATE + AMODIAQUINE |
Coarsucam |
Malaria |
ARAMF_C_05370 |
NA |
||
ARTESUNATE + AMODIAQUINE |
Coarsucam |
Malaria |
ARAMF_L_04314 |
NA |
||
ATACIGUAT |
Not marketed |
Pain, Neuropathic |
DFI10569 |
SERENEATI |
||
ATACIGUAT |
Not marketed |
Peripheral Arterial Disease |
DFI6174 |
ACCELA |
||
ATORVASTATIN/IRBESARTAN |
Rovelito |
Diabetes Mellitus, Type 2 |
ATOIRL07827 |
NA |
||
AVANAFIL |
Spedra |
Erectile Dysfuntion |
AVANAL07163 |
CEDAR |
||
References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted